J Immunol Methods 2005, 298: 61–72.PubMedCrossRef 19. Lin W, Voskens CJ, Zhang X, Schindler DG, Wood A, Burch E, Wei Y, Chen L, Tian
G, Tamada K, Wang LX, Schulze DH, Mann D, Strome SE: Fc-dependent expression of CD137 on human NK cells: insights into “”agonistic”" effects of anti-CD137 monoclonal antibodies. Blood 2008, 112: 699–707.PubMedCrossRef 20. Kabelitz D, Wesch SIS3 cell line D, He W: Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007, 67: 5–8.PubMedCrossRef 21. Lanier LL: NK cell recognition. Annu Rev Immunol 2005, 23: 225–274.PubMedCrossRef 22. Becknell B, Caligiuri MA: Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005, 86: 209–239.PubMedCrossRef 23. Brooks MG132 AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE: NKG2A complexed with CD94 defines a novel inhibitory natural
killer cell receptor. J Exp Med 1997, 185: 795–800.PubMedCrossRef 24. Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391: 795–799.PubMedCrossRef 25. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I, Maenaka K: Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003, 100: 8856–8861.PubMedCrossRef 26. Morton DL, Goodnight JE Jr: Clinical trials of immunotherapy: present status. Cancer 1978, 42: 2224–2233. tuclazepam PubMedCrossRef 27. Disis ML, Bernhard H, Jaffee EM: Use of tumour-responsive T cells as cancer treatment. Lancet 2009, 373: 673–683.PubMedCrossRef 28. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E: Antibody-dependent cellular cytotoxicity
mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13: 1552–1561.PubMedCrossRef 29. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK, Bunn PA Jr: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11: 795–805.PubMed 30. Riddell SR, Appelbaum FR: Graft-versus-host disease: a surge of developments. PLoS Med 2007, 4: e198.PubMedCrossRef 31. North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, Anderson R, Lowdell MW: Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 2007, 178: 85–94.PubMed 32.
Related posts:
- Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
- Gastroenterology 2005, 128:1229–1242 PubMedCrossRef 11 Torres LE
- Nucleic Acids Res 1990,18(22):6531–6535 PubMedCrossRef 10 Yoshid
- PubMedCrossRef 14 Lichtenthaler HK, Rohmer M, Schwender J: Two i
- J Bacteriol
2006,188(6):2290–2293 PubMedCrossRef 17 Mars